A circulating miRNA assay as a first-line test for prostate cancer screening.

Prostate cancer (PCa) screening currently relies on prostate-specific antigen (PSA) testing and digital rectal examination. However, recent large-scale studies have questioned the long-term efficacy of these tests, and biomarkers that accurately identify PCa are needed.

We analysed the levels of circulating microRNAs (miRNAs) in patients with elevated PSA who were diagnosed with either localised PCa (n=36) or benign prostatic hyperplasia (BPH, n=31) upon biopsy. Real-time RT-PCR with Taqman probes was used to measure plasma levels of miRNAs. To circumvent problems associated with circulating miRNA quantitation, we computed the expression ratios of upregulated and downregulated miRNAs.

The miR-106a/miR-130b and miR-106a/miR-223 ratios were significantly different between the biopsy-positive and BPH groups (P<0.0001), and yielded statistical power values that were >0.99. Both miRNA ratios were highly sensitive and more specific than PSA in discriminating localised PCa from BPH. Receiver operating characteristic curve analysis revealed area under curve values of 0.81 (miR-106a/miR-130b) and 0.77 (miR-106a/miR-223).

Testing for circulating miR-106a/miR-130b and miR-106a/miR-223 ratios may reduce the costs and morbidity of unnecessary biopsies and is feasible for large-scale screening, as it requires measuring only three miRNAs.British Journal of Cancer advance online publication, 26 May 2016; doi:10.1038/bjc.2016.151 www.bjcancer.com.

British journal of cancer. 2016 May 26 [Epub ahead of print]

Evgeniya Sharova, Angela Grassi, Anna Marcer, Katia Ruggero, Francesco Pinto, Pierfrancesco Bassi, Paola Zanovello, Filiberto Zattoni, Donna M D'Agostino, Massimo Iafrate, Vincenzo Ciminale

Veneto Institute of Oncology, IRCCS, Immunology and Molecular Oncology Unit, via Gattamelata 64, 35128 Padova, Italy., Department of Surgery, Oncology and Gastroenterology, University of Padova, via Gattamelata 64, 35128 Padova, Italy., Department of Surgery, Oncology and Gastroenterology, University of Padova, via Gattamelata 64, 35128 Padova, Italy., Department of Surgery, Oncology and Gastroenterology, University of Padova, via Gattamelata 64, 35128 Padova, Italy., Department of Urology, University of Rome La Cattolica, Largo Francesco Vito 1, 00168 Rome, Italy., Department of Urology, University of Rome La Cattolica, Largo Francesco Vito 1, 00168 Rome, Italy., Veneto Institute of Oncology, IRCCS, Immunology and Molecular Oncology Unit, via Gattamelata 64, 35128 Padova, Italy., Department of Surgery, Oncology and Gastroenterology, University of Padova, via Gattamelata 64, 35128 Padova, Italy., Department of Biomedical Sciences, University of Padova, via Ugo Bassi 58/B, 35121 Padova, Italy., Department of Surgery, Oncology and Gastroenterology, University of Padova, via Gattamelata 64, 35128 Padova, Italy., Veneto Institute of Oncology, IRCCS, Immunology and Molecular Oncology Unit, via Gattamelata 64, 35128 Padova, Italy.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe